Related Experiment Video
Updated: Aug 21, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Metabolic Dysfunction-associated Steatotic Liver Disease in Romania: A Multidisciplinary Position Paper on
Liliana-Simona Gheorghe1, Jeffrey V Lazarus2, Heiner Wedemeyer3
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Fundeni Clinical Institute, Bucharest, Romania. drlgheorghe@gmail.com.
Background And Aims:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease globally and a rising cause of cirrhosis, hepatocellular carcinoma, liver transplantation, cardiovascular events and impaired quality of life. In Romania, a 30-33% adult prevalence would correspond to approximately 4.5-5.1 million adults with MASLD, including an estimated 225,000-410,000 with the progressive phenotype of metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. In May 2026, a national multidisciplinary initiative was launched to support a coordinated response aligned with the World Health Assembly. draft resolution on steatotic liver disease.
Methods:
The 3rd Romanian Forum of Metabolic Hepatology (Bucharest, 12 March 2026), co-hosted by Romanian Society of Gastroenterology and Hepatology (SRGH) and Romanian Association for Liver Diseases (RoALD), convened hepatology, primary care, metabolic, cardiovascular, renal, respiratory, ENT, transfusion medicine, public health, policy and patient representatives. Evidence, Romanian estimates, EASL-EASD-EASO 2024 guidance and policy documents were reviewed and refined into ten consensus statements.
Results:
The statements address burden, nomenclature, policy gaps, MASLD phenotypes, metabolic dysfunction and alcohol-associated liver disease (MetALD), integration within the cardio-reno-hepato-metabolic/non-communicable diseases framework, fibrosis-4 index (FIB-4) based case-finding, cross-specialty prescribing, a Romanian clinical care pathway and a national action plan including quality-of-life outcomes and access to EU-approved resmetirom for eligible adults with non-cirrhotic MASH and F2-F3 fibrosis.
Conclusions:
This position paper provides a Romanian framework for MASLD prevention, detection and care, requiring coordinated action by professional societies, health authorities, the Romanian National Health Insurance Agency (CNAS), primary care, patient organisations and civil society.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Cirrhosis I: Introduction
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Acute Pancreatitis II: Clinical Manifestations and Management

